drugset / Trial / NCT05268692

Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP

NCT05268692

Phase 2/3 Recruiting 500 enrolled Kochi University
RandomizedSequentialOpen-labelTreatment

Summary

The effect of neoadjuvant chemotherapy for pancreatic cancer was gradually established. However it has been not clarified which regimen of neoadjuvant treatment for pancreatic cancer is the best.

Timeline

Start
2019-01-01
Primary completion
2025-12-31
Completion
2030-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gemcitabine Small molecule 800 mg/m2 Intravenous
Comparator Paclitaxel Small molecule 100 mg/m2 Intravenous
Comparator S-1 Small molecule 60 mg Oral
Comparator S-1 Small molecule 80 mg Oral
Comparator S-1 Small molecule 100 mg Oral